A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent

Trial Profile

A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agent

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate 275
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 01 Aug 2017 Last checked against European Clinical Trials Database record.
    • 06 Jun 2017 Results (n=168) assessing the impact of nivolumab on health-related quality of life (HRQoL), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2017 According to a Bristol-Myers Squibb media release, the European Commission (EC) has approved Opdivo (nivolumab) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-containing therapy. The approval was based on result from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top